JP7471298B2 - アセチル－ロイシンの重水素化類似体 - Google Patents

アセチル－ロイシンの重水素化類似体 Download PDF

Info

Publication number
JP7471298B2
JP7471298B2 JP2021531964A JP2021531964A JP7471298B2 JP 7471298 B2 JP7471298 B2 JP 7471298B2 JP 2021531964 A JP2021531964 A JP 2021531964A JP 2021531964 A JP2021531964 A JP 2021531964A JP 7471298 B2 JP7471298 B2 JP 7471298B2
Authority
JP
Japan
Prior art keywords
compound
subject
present disclosure
pharma
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021531964A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022514823A (ja
JP2022514823A5 (enExample
Inventor
美智子 マン
Original Assignee
イントラビオ エルティーディー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イントラビオ エルティーディー filed Critical イントラビオ エルティーディー
Publication of JP2022514823A publication Critical patent/JP2022514823A/ja
Publication of JP2022514823A5 publication Critical patent/JP2022514823A5/ja
Priority to JP2024062686A priority Critical patent/JP2024095769A/ja
Application granted granted Critical
Publication of JP7471298B2 publication Critical patent/JP7471298B2/ja
Priority to JP2025178241A priority patent/JP2026016521A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/001—Acyclic or carbocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/47—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021531964A 2018-12-06 2019-12-06 アセチル－ロイシンの重水素化類似体 Active JP7471298B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2024062686A JP2024095769A (ja) 2018-12-06 2024-04-09 アセチル－ロイシンの重水素化類似体
JP2025178241A JP2026016521A (ja) 2018-12-06 2025-10-23 アセチル－ロイシンの重水素化類似体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862776297P 2018-12-06 2018-12-06
US62/776,297 2018-12-06
PCT/IB2019/060525 WO2020115715A1 (en) 2018-12-06 2019-12-06 Deuterated analogs of acetyl-leucine

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024062686A Division JP2024095769A (ja) 2018-12-06 2024-04-09 アセチル－ロイシンの重水素化類似体

Publications (3)

Publication Number Publication Date
JP2022514823A JP2022514823A (ja) 2022-02-16
JP2022514823A5 JP2022514823A5 (enExample) 2022-12-15
JP7471298B2 true JP7471298B2 (ja) 2024-04-19

Family

ID=68887086

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2021531964A Active JP7471298B2 (ja) 2018-12-06 2019-12-06 アセチル－ロイシンの重水素化類似体
JP2024062686A Withdrawn JP2024095769A (ja) 2018-12-06 2024-04-09 アセチル－ロイシンの重水素化類似体
JP2025178241A Pending JP2026016521A (ja) 2018-12-06 2025-10-23 アセチル－ロイシンの重水素化類似体

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2024062686A Withdrawn JP2024095769A (ja) 2018-12-06 2024-04-09 アセチル－ロイシンの重水素化類似体
JP2025178241A Pending JP2026016521A (ja) 2018-12-06 2025-10-23 アセチル－ロイシンの重水素化類似体

Country Status (13)

Country Link
US (2) US12145899B2 (enExample)
EP (1) EP3886986A1 (enExample)
JP (3) JP7471298B2 (enExample)
KR (2) KR102765448B1 (enExample)
CN (2) CN113348018B (enExample)
AU (1) AU2019391434B2 (enExample)
BR (1) BR112021010923A2 (enExample)
IL (2) IL319687A (enExample)
MA (1) MA54289A (enExample)
MX (2) MX2021006559A (enExample)
SA (1) SA521422185B1 (enExample)
SG (1) SG11202106009TA (enExample)
WO (1) WO2020115715A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024095769A (ja) * 2018-12-06 2024-07-10 イントラビオ エルティーディー アセチル－ロイシンの重水素化類似体

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201709459D0 (en) 2017-06-14 2017-07-26 Intrabio Ltd Treatment for migraine
WO2022264037A1 (en) * 2021-06-14 2022-12-22 Intrabio Ltd. Branched-chain amino acid derivatives to treat disease
US12403111B2 (en) 2024-02-02 2025-09-02 SynGAP Research Fund Compositions and methods for treating neurodevelopmental disorders

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016513084A (ja) 2013-02-05 2016-05-12 インファール・アクティエンゲゼルシャフト 位置特異的非対称重水素富化カテコールアミン誘導体および前記化合物を含有する医薬
WO2018029658A1 (en) 2016-08-11 2018-02-15 Intrabio Limited Therapeutic agents for neurodegenerative diseases

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2293638T3 (es) * 1994-03-25 2008-03-16 Isotechnika, Inc. Mejora de la eficacia de farmacos por deuteracion.
US20060063827A1 (en) 2004-09-23 2006-03-23 Yu Ruey J Systemic administration of therapeutic amino acids and N-acetylamino acids
US20050026823A1 (en) * 2003-06-20 2005-02-03 Biomarin Pharmaceutical Inc. Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues
US20120101168A1 (en) * 2010-10-26 2012-04-26 Eliezer Bahar Deuterium enriched rasagiline
ES2994242T3 (en) * 2016-04-19 2025-02-05 Intrabio Ltd Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility
DK3359146T3 (en) * 2016-08-11 2019-04-08 Intrabio Ltd PHARMACEUTICAL COMPOSITIONS AND USES AGAINST LYSOSOMAL STORAGE DISEASES
HUE062729T2 (hu) 2017-03-28 2023-12-28 Intrabio Ltd Betahisztin, vagy gyógyászatilag elfogadható sója, és egy monoamin-oxidáz inhibitor, egy alanyban szédülés egy vagy több tünete kezelésében vagy megelõzésében történõ alkalmazásra
GB201709459D0 (en) 2017-06-14 2017-07-26 Intrabio Ltd Treatment for migraine
US12458614B2 (en) 2017-10-18 2025-11-04 Intrabio Ltd Therapeutic agents for improved mobility and cognitive function and for treating neurodegenerative diseases and lysosomal storage disorders
MA51836B1 (fr) 2018-02-15 2025-01-31 Intrabio Ltd Agents thérapeutiques permettant de traiter le syndrome des jambes sans repos
EP3886986A1 (en) 2018-12-06 2021-10-06 IntraBio Ltd Deuterated analogs of acetyl-leucine
US10950670B2 (en) * 2018-12-17 2021-03-16 Wuhan China Star Optoelectronics Semiconductor Display Technology Co., Ltd. Display panel
SMT202400334T1 (it) * 2019-03-02 2024-09-16 Intrabio Ltd (n-)acetil-l-leucina per il trattamento di lesioni cerebrali traumatiche
RS67283B1 (sr) 2019-06-28 2025-11-28 Intrabio Ltd Kombinovana terapija sa acetil-leucinom i miglustatom za lečenje bolesti lizozomskog skladištenja
WO2021144720A1 (en) * 2020-01-13 2021-07-22 Intrabio Ltd Treatment of late-onset neurodegenerative diseases in heterozygous npc1 gene mutation carriers
US20230201150A1 (en) * 2020-05-22 2023-06-29 Intrabio Ltd. The combination of acetyl leucine and 4-aminopyridine or acetazolamide for treating ataxia

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016513084A (ja) 2013-02-05 2016-05-12 インファール・アクティエンゲゼルシャフト 位置特異的非対称重水素富化カテコールアミン誘導体および前記化合物を含有する医薬
WO2018029658A1 (en) 2016-08-11 2018-02-15 Intrabio Limited Therapeutic agents for neurodegenerative diseases

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
Drug News & Perspectives，2010年，Vol.23(6)，p.398-404
Huaxue，1991年，Vol.49(4)，p.257-260
Journal Biomol. NMR，2013年，Vol.57，p.237-249
Journal of Organic Chemistry，2001年，Vol.66(17)，p.5919-5922
Journal of Structural Chemistry，1998年，Vol.29(2)，p.216-220
Khimiya Vysokikh Energii，1986年，Vol.20(5)，p.430-435
Organic & Biomolecular Chemistry，2005年，Vol.3(8)，p.1435-1447
Organic Chemistry，1995年，Vol.12，p.1603-1609
Tetrahedron Letters，1985年，Vol.26(36)，p.4387-4390

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024095769A (ja) * 2018-12-06 2024-07-10 イントラビオ エルティーディー アセチル－ロイシンの重水素化類似体

Also Published As

Publication number Publication date
IL283673B1 (en) 2025-04-01
BR112021010923A2 (pt) 2021-08-24
KR102765448B1 (ko) 2025-02-07
EP3886986A1 (en) 2021-10-06
CN120157593A (zh) 2025-06-17
IL283673B2 (en) 2025-08-01
KR20250022899A (ko) 2025-02-17
JP2022514823A (ja) 2022-02-16
JP2026016521A (ja) 2026-02-03
AU2019391434B2 (en) 2025-01-09
WO2020115715A1 (en) 2020-06-11
JP2024095769A (ja) 2024-07-10
US12145899B2 (en) 2024-11-19
CN113348018B (zh) 2025-04-01
AU2019391434A1 (en) 2021-07-08
US20250129011A1 (en) 2025-04-24
IL319687A (en) 2025-05-01
US20220024858A1 (en) 2022-01-27
MA54289A (fr) 2021-10-06
CA3122223A1 (en) 2020-06-11
KR20210111757A (ko) 2021-09-13
SG11202106009TA (en) 2021-07-29
MX2024005670A (es) 2024-05-30
SA521422185B1 (ar) 2024-04-24
CN113348018A (zh) 2021-09-03
IL283673A (en) 2021-07-29
MX2021006559A (es) 2021-08-16

Similar Documents

Publication Publication Date Title
US20250129011A1 (en) Deuterated analogs of acetyl-leucine
JP5303458B2 (ja) β−グルコセレブロシダーゼの活性増強による神経学的疾患の治療方法
JP6320931B2 (ja) リソソーム酵素を再構成する能力を有する化合物ならびにアンブロキソールおよび／またはアンブロキソールの誘導体の組み合わせ
JP5634498B2 (ja) 中枢神経系の変性障害の予防および／または治療方法
JP2026001009A (ja) リソソーム蓄積性疾患と関連する神経学的症状を処置するための方法
TW202337456A (zh) Ｇｍ２神經節苷脂症之治療
EP3989962B1 (en) Combination therapy with acetyl-leucine and miglustat for treating a lysosomal storage disease
BR112021015172A2 (pt) Métodos de tratamento de sintomas e distúrbios associados a doenças de armazenamento lisossomal
US20260108494A1 (en) Therapeutic agent for non-motor symptoms associated with parkinson's disease
RU2810793C2 (ru) Дейтерированные аналоги ацетиллейцина
US20240024302A1 (en) SOLUBLE EPOXIDE HYDROLASE (sEH) INHIBITORS AND DUAL COX/sEH INHIBITORS FOR THE TREATMENT OF ARRHYTHMOGENIC CARDIOMYOPATHY
CA3122223C (en) Deuterated analogs of acetyl-leucine
US20240208895A1 (en) Branched-chain amino acid derivatives to treat disease
EP3944858A1 (en) Combination product containing trehalose and miglustat for treating lysosomal diseases
HK40127928A (en) Combination therapy with acetyl-leucine and miglustat for treating a lysosomal storage disease
HK40017297A (en) Therapeutic agent for non-motor symptoms associated with parkinson's disease

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221205

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20221205

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221205

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20231026

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231031

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240130

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240312

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240409

R150 Certificate of patent or registration of utility model

Ref document number: 7471298

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150